<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00600262</url>
  </required_header>
  <id_info>
    <org_study_id>APEC-004</org_study_id>
    <nct_id>NCT00600262</nct_id>
  </id_info>
  <brief_title>Intravitreal Bevacizumab for Diabetic Retinopathy</brief_title>
  <official_title>Efficacy of Intravitreal Bevacizumab for Severe Nonproliferative and Proliferative Diabetic Retinopathy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asociación para Evitar la Ceguera en México</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asociación para Evitar la Ceguera en México</source>
  <brief_summary>
    <textblock>
      Background: to evaluate the 3-month efficacy of a single dose of intravitreal bevacizumab on
      the progression of severe non proliferative diabetic retinopathy, proliferative diabetic
      retinopathy and active photocoagulated diabetic proliferative by evaluation of ischemic areas
      and regression of retinal and disc neovasculrization.

      Methods: 40 patients were enrolled in a prospective, interventional study. Patients were
      treated with intravitreal bevacizumab 0.1ml (0.25mg). We evaluated visual acuity,
      neovascularization leakage points, capillary closure ischemic areas and macular edema by
      clinical examination and fluorescein angiography. A clinical examination was performed at
      baseline and days 1,14 and 30. Active leakage points were measured by fluorescein angiography
      at 30 days.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2005</start_date>
  <completion_date>June 2006</completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Severe Nonproliferative</condition>
  <condition>Proliferative Diabetic Retinopathy</condition>
  <condition>Active Photocoagulated Diabetic Retinopathy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>intravitreal bevacizumab</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Severe nonproliferative

          -  Proliferative diabetic retinopathy

          -  Active photocoagulated diabetic retinopathy

        Exclusion Criteria:

          -  Previous vascular occlusion

          -  Glaucoma

          -  Uncontrolled hypertension, thromboembolic event

          -  Renal abnormalities

          -  Recent or planned surgery

          -  Coagulation abnormalities

          -  Panretinal photocoagulation of less than one month before

          -  Patients with known serious allergies
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elizabeth Reyna-Castelan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asociación para evitar la ceguera en Mexico</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mariana Martinez-Castellanos, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Asociación para Evitar la Ceguera en México</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Elizabeth Reyna Castelan</name>
      <address>
        <city>Mexico City</city>
        <zip>04030</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>January 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 29, 2006</study_first_submitted>
  <study_first_submitted_qc>January 23, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 24, 2008</study_first_posted>
  <last_update_submitted>January 23, 2008</last_update_submitted>
  <last_update_submitted_qc>January 23, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 24, 2008</last_update_posted>
  <keyword>severe nonproliferative</keyword>
  <keyword>proliferative diabetic retinopathy</keyword>
  <keyword>active photocoagulated diabetic retinopathy</keyword>
  <keyword>intravitreal bevacizumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Diabetic Retinopathy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

